UNSPSC 51451604: Oxfendazole

This classification denotes an antihelminthic agent with the molecular formula C15H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OMP2H17F9E, chemically known as 2-benzimidazolecarbamic acid, 5-(phenylsulfinyl)-, methyl ester but generally known as oxfendazole, which bears US NIH Compound Identifier 40854. European Medicines Agency schedules Oxfendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09519MIG.

UNSPSC 51451604 Oxfendazole is a Commodity code that nominally names a single antiparasitic pharmaceutical product, but the recent state and local opportunities tagged under it actually span a broader range of pharmaceuticals, medical supplies, and pharmacy benefit management services. The code sees procurement activity across health departments, fire rescue divisions, and cooperative purchasing alliances—jurisdictions acquiring naloxone, medical emergency supplies, generic pharmaceuticals, and over-the-counter products for public health and first-responder use. The actual buying reflects pharmacy procurement scaled to government operations rather than a narrowly defined single-drug category.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery, response deadline July 26, 2023. The City of Tampa released ITB 26P00145 on March 25, 2026 for medical and first aid supplies supporting the Fire Department Rescue Division—169 line items of respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, and consumables with a March 13, 2026 deadline and an estimated contract value of $700,000.00, designated as a sheltered Small Local Business Enterprise (SLBE) procurement with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for state and local government facilities including Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities outside traditional pharmacy benefit manager arrangements. The code shows activity primarily in regional fire rescue, county health, state pharmacy, and multistate cooperative purchasing channels rather than monolithic state pharmaceutical procurement.